Whittier Trust Co. of Nevada Inc. Grows Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Whittier Trust Co. of Nevada Inc. increased its stake in Thermo Fisher Scientific by 1.4% during the 2nd quarter, bringing its holdings to 41,759 shares valued at approximately $16.93 million.
• Several institutional investors, including Brighton Jones LLC and GAMMA Investing LLC, have also increased their positions in Thermo Fisher Scientific, reflecting growing confidence in the company's prospects.
• Thermo Fisher Scientific reported earnings of $5.36 per share, exceeding analyst expectations, with revenue rising 2.9% year-over-year, indicating solid operational performance.

Whittier Trust Co. of Nevada Inc. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 41,759 shares of the medical research company's stock after purchasing an additional 570 shares during the period. Whittier Trust Co. of Nevada Inc.'s holdings in Thermo Fisher Scientific were worth $16,931,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of TMO. Brighton Jones LLC increased its position in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares during the last quarter. PFG Investments LLC increased its position in shares of Thermo Fisher Scientific by 4.0% in the 1st quarter. PFG Investments LLC now owns 2,222 shares of the medical research company's stock worth $1,106,000 after purchasing an additional 86 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its position in shares of Thermo Fisher Scientific by 1.8% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 38,154 shares of the medical research company's stock worth $18,986,000 after purchasing an additional 691 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Up 0.9%

TMO stock opened at $544.02 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm has a market cap of $205.43 billion, a PE ratio of 31.46, a P/E/G ratio of 2.93 and a beta of 0.77. The firm has a 50 day simple moving average of $497.37 and a 200 day simple moving average of $449.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 earnings per share. The firm's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, October 12th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Barclays boosted their price objective on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a research report on Thursday, October 2nd. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $589.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.